Medication Reconciliation Associated with Comprehensive Geriatric Assessment in Older Patients with Cancer: ChimioAge Study.
aged
antineoplastic protocols
geriatric assessment
medication reconciliation
treatment failure
Journal
Clinical interventions in aging
ISSN: 1178-1998
Titre abrégé: Clin Interv Aging
Pays: New Zealand
ID NLM: 101273480
Informations de publication
Date de publication:
2020
2020
Historique:
received:
14
05
2020
accepted:
30
07
2020
entrez:
28
9
2020
pubmed:
29
9
2020
medline:
13
1
2021
Statut:
epublish
Résumé
Polymorbidity induces polypharmacy in older patients may lead to potential drug-drug interactions (DDI) which can modify the tolerance and safety of oncological treatments and alter the intended therapeutic effect. The objective of our study was to describe the decision-making process for oncological treatment and related outcomes, in a population of older adults undergoing a comprehensive geriatric assessment (CGA) associated to a comprehensive medication reconciliation (CMR) prior to initiating oncological treatment. ChimioAge is a prospective observational study conducted between 01/2017 and 07/2018 at Marseille University Hospital and approved by the French National Ethics Committee. It comprised all consecutive patients aged 70 years and over who were referred for a CGA as part of CMR, before initiating systemic treatment. One hundred and seventy-one cancer patients were included. Mean age was 79.2 years, over half had metastatic cancers, 75% had an ECOG performance status zero or one, and two-thirds were independent in daily activities. Two-thirds of the patients had polypharmacy and the CMR identified potential DDI with systemic treatment in 43.3% of patients. Following the CGA, the CMR and the hospital oncologists decision, 30% of the patients received adapted systemic treatment with reduced doses at initiation. They presented fewer toxicities - irrespective of grade and type - than patients who received standard treatment (p<0.001) and had comparable overall survival (Log rank p=0.21). This is one of the first studies to highlight the value in conducting CMR and a CGA simultaneously before initiating systemic treatment in older patients with cancer. These two evaluations could give oncologists decisive information to personalize cancer treatment of older patients and optimize treatment dose to offer the best efficacy and minimize toxicity.
Sections du résumé
BACKGROUND
BACKGROUND
Polymorbidity induces polypharmacy in older patients may lead to potential drug-drug interactions (DDI) which can modify the tolerance and safety of oncological treatments and alter the intended therapeutic effect. The objective of our study was to describe the decision-making process for oncological treatment and related outcomes, in a population of older adults undergoing a comprehensive geriatric assessment (CGA) associated to a comprehensive medication reconciliation (CMR) prior to initiating oncological treatment.
METHODS
METHODS
ChimioAge is a prospective observational study conducted between 01/2017 and 07/2018 at Marseille University Hospital and approved by the French National Ethics Committee. It comprised all consecutive patients aged 70 years and over who were referred for a CGA as part of CMR, before initiating systemic treatment.
RESULTS
RESULTS
One hundred and seventy-one cancer patients were included. Mean age was 79.2 years, over half had metastatic cancers, 75% had an ECOG performance status zero or one, and two-thirds were independent in daily activities. Two-thirds of the patients had polypharmacy and the CMR identified potential DDI with systemic treatment in 43.3% of patients. Following the CGA, the CMR and the hospital oncologists decision, 30% of the patients received adapted systemic treatment with reduced doses at initiation. They presented fewer toxicities - irrespective of grade and type - than patients who received standard treatment (p<0.001) and had comparable overall survival (Log rank p=0.21).
CONCLUSION
CONCLUSIONS
This is one of the first studies to highlight the value in conducting CMR and a CGA simultaneously before initiating systemic treatment in older patients with cancer. These two evaluations could give oncologists decisive information to personalize cancer treatment of older patients and optimize treatment dose to offer the best efficacy and minimize toxicity.
Identifiants
pubmed: 32982194
doi: 10.2147/CIA.S262209
pii: 262209
pmc: PMC7489933
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1587-1598Informations de copyright
© 2020 Couderc et al.
Déclaration de conflit d'intérêts
Laurent Greillier reports personal fees and non-financial support from ABBVIE, ASTRA-ZENECA, BOEHRINGER INGELHEIM, BMS, MSD, and ROCHE and personal fees from TAKEDA, outside the submitted work. The authors report no other potential conflicts of interest for this work.
Références
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Arch Gerontol Geriatr. 2009 Mar-Apr;48(2):222-6
pubmed: 18336933
Curr Oncol. 2016 Jun;23(3):144-53
pubmed: 27330342
J Clin Oncol. 2012 May 20;30(15):1829-34
pubmed: 22508806
J Geriatr Oncol. 2019 Nov;10(6):884-894
pubmed: 30824222
J Geriatr Oncol. 2013 Jan;4(1):64-70
pubmed: 23525607
J Clin Oncol. 2016 May 1;34(13):1476-83
pubmed: 26884557
Cancer J. 2017 Jul/Aug;23(4):211-218
pubmed: 28731943
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Cancer Manag Res. 2018 Aug 29;10:3015-3021
pubmed: 30214296
JAMA. 1963 Sep 21;185:914-9
pubmed: 14044222
Br J Cancer. 2015 Apr 28;112(9):1435-44
pubmed: 25871332
J Am Geriatr Soc. 1991 Feb;39(2):142-8
pubmed: 1991946
J Geriatr Oncol. 2020 May;11(4):586-592
pubmed: 31445850
Ann Oncol. 2018 Aug 1;29(8):1718-1726
pubmed: 30010772
PLoS One. 2014 Dec 11;9(12):e115060
pubmed: 25503576
Ann Oncol. 2013 Nov;24(11):2808-13
pubmed: 24061628
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
Gerontologist. 1969 Autumn;9(3):179-86
pubmed: 5349366
J Clin Oncol. 2014 Nov 10;32(32):3634-42
pubmed: 25267757
Age Ageing. 1988 Jul;17(4):227-35
pubmed: 3177082
Age Ageing. 2015 Mar;44(2):213-8
pubmed: 25324330
Clin Pharmacokinet. 1996 Jul;31(1):47-64
pubmed: 8827399
J Geriatr Oncol. 2018 Sep;9(5):526-533
pubmed: 29510896
Psychiatry Res. 1992 Mar;41(3):237-48
pubmed: 1594710
J Clin Oncol. 2013 Apr 10;31(11):1464-70
pubmed: 23460711
Age Ageing. 2019 Jul 1;48(4):601
pubmed: 31081853
J Clin Pharm Ther. 2016 Apr;41(2):128-44
pubmed: 26913812
Lancet Oncol. 2015 Jul;16(7):e333-41
pubmed: 26149885
J Clin Oncol. 2011 Apr 1;29(10):1290-6
pubmed: 21357782
J Geriatr Oncol. 2019 Nov;10(6):937-943
pubmed: 31085136
Crit Rev Oncol Hematol. 2008 May;66(2):163-70
pubmed: 18243726
Aging Med (Milton). 2019 Feb 14;2(1):42-49
pubmed: 31942511
J Am Geriatr Soc. 2006 Jul;54(7):1119-24
pubmed: 16866685
Cancer. 2012 Jul 1;118(13):3377-86
pubmed: 22072065
Acta Oncol. 2016 Jan;55(1):15-23
pubmed: 26271800
J Geriatr Oncol. 2014 Jul;5(3):307-14
pubmed: 24821377
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Psychopharmacol Bull. 1988;24(4):709-11
pubmed: 3249773
J Clin Oncol. 2018 Aug 1;36(22):2326-2347
pubmed: 29782209
J Geriatr Oncol. 2013 Jul;4(3):227-34
pubmed: 23795224
J Oncol Pharm Pract. 2019 Apr;25(3):765-768
pubmed: 29950148
Eur J Hosp Pharm. 2018 Jan;25(1):21-25
pubmed: 31156980
J Clin Pharm Ther. 2017 Aug;42(4):414-424
pubmed: 28556392
J Cancer Res Clin Oncol. 2018 Mar;144(3):571-577
pubmed: 29299751
Rev Med Suisse. 2011 May 25;7(296):1149-50, 1152-3
pubmed: 21721206
J Am Geriatr Soc. 1997 Jun;45(6):735-8
pubmed: 9180669
Breast J. 2009 Jul-Aug;15(4):404-8
pubmed: 19508671
Interdiscip Top Gerontol. 2013;38:61-72
pubmed: 23503516
Br J Cancer. 2014 Dec 9;111(12):2224-8
pubmed: 25268369
Br J Clin Pharmacol. 2019 Apr;85(4):838-844
pubmed: 30681181
J Geriatr Oncol. 2018 Sep;9(5):430-440
pubmed: 29631898
J Clin Oncol. 2011 Oct 10;29(29):3921-6
pubmed: 21911719
Oncologist. 2014 Mar;19(3):275-82
pubmed: 24569945